[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA: a cancer journal for clinicians, 2018, 68(6): 394~424. [2] Shaker H, Bundred N J, Landberg G, et al. Breast cancer stromal clotting activation (tissue factor and thrombin): a pre-invasive phenomena that is prognostic in invasion[J]. Cancer medicine, 2020, 9(5): 1768~1778. [3] 梁骑,李君安,邓健康,等.乳腺癌患者血浆纤维蛋白原和D-二聚体及抗凝血酶Ⅲ活性水平的变化及临床意义[J].中国医药,2020,15(6):890~893. [4] Toesca A, Peradze N, Manconi A, et al. Robotic nipple-sparing mastectomy for the treatment of breast cancer: feasibility and safety study[J]. The Breast, 2017, 31: 51~56. [5] Kuo W L, Huang J J, Huang Y T, et al. Robot-assisted mastectomy followed by immediate autologous microsurgical free flap reconstruction: techniques and feasibility in three different breast cancer surgical scenarios[J]. Clinical Breast Cancer, 2020, 20(1): e1~e8. [6] Johnson K E, Forward J A, Tippy M D, et al. Tamoxifen directly inhibits platelet angiogenic potential and platelet-mediated metastasis[J]. Arteriosclerosis, thrombosis, and vascular biology,2017,37(4):664~674. [7] Pather K, Dix-Peek T, Duarte R, et al. Breast cancer cell-induced platelet activation is compounded by tamoxifen and anastrozole in vitro[J]. Thrombosis research, 2019, 177: 51~58. [8] Xu X, Chlebowski R T, Shi J, et al. Aromatase inhibitor and tamoxifen use and the risk of venous thromboembolism in breast cancer survivors[J]. Breast cancer research and treatment, 2019, 174(3): 785~794. [9] Thein K Z, Ball S, Zaw M H, et al. 1691P updated meta-analysis of randomized controlled trials (RCTs) to determine the CDK 4/6 inhibitors associated venous thromboembolism (VTE) risk in hormone receptor-positive breast cancer (BC) patients[J]. Annals of Oncology, 2018, 29(8):300~308. [10] Tsukamoto J, Monteiro M, Vale S, et al. Thromboembolic events related to treatment with checkpoint inhibitors: report of two cases[J]. Case reports in oncology, 2018, 11(3): 648~653. [11] Abbas W, Dixit G, Rao R R, et al. Immunotherapy-induced acute pulmonary thromboembolism: a case report[J]. South Asian journal of cancer, 2019, 8(3): 172. [12] Chopra V, Kaatz S, Grant P, et al. Risk of venous thromboembolism following peripherally inserted central catheter exchange: an analysis of 23,000 hospitalized patients[J]. The American journal of medicine, 2018, 131(6): 651~660. [13] Castle J, Harvey J R, Clarke R, et al. Update for: Thrombin inhibition preoperatively (TIP) in early breast cancer, the first clinical trial of DOACs as an anti-cancer agent[J]. Thrombosis Research, 2018, 164: S224~S225. [14] Farge D, Frere C, Connors J M, et al. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer[J]. The Lancet Oncology, 2019.
2020, Vol. 26 
冀公网安备13080202000677号